Previous 10 | Next 10 |
ACTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2022. The Company also announced a cash quarterly divid...
Psychemedics press release ( NASDAQ: PMD ): Q2 GAAP EPS of -$0.06. Revenue of $6.51M (+6.9% Y/Y). For further details see: Psychemedics GAAP EPS of -$0.06, revenue of $6.51M
ACTON, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2022. The Company also announced a quarterly dividend of $0...
ACTON, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD) announced today that it will be nominating Peter H. Kamin and Darius G. Nevin to serve as new members of its Board of Directors at its upcoming Annual Meeting of Stockholders to be held on Augus...
Psychemedics (PMD) declares $0.07/share quarterly dividend, 40% increase from prior dividend of $0.05. Forward yield 4.56% Payable June 24; for shareholders of record May 27; ex-div May 26. See PMD Dividend Scorecard, Yield Chart, & Dividend Growth. For further details see: Psycheme...
Psychemedics press release (NASDAQ:PMD): Q1 GAAP EPS of $0.01. Revenue of $6.5M (+14.0% Y/Y). For further details see: Psychemedics GAAP EPS of $0.01, revenue of $6.5M
ACTON, Mass., May 10, 2022 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2022, and the declaration of a cash dividend of $0.07 per sh...
21% YoY revenue growth in Q4, gross margins surge 1,000bps YoY. EPS loss of $0.29 on higher legal costs and a one-time expense. Company paid a dividend of $0.05/share in December and is evaluating options for 2022. 11% FCF yield on “normal” 2023 estimates. Ma...
Psychemedics press release (NASDAQ:PMD): Q4 GAAP EPS of -$0.29. Revenue of $6.44M (+20.6% Y/Y). For further details see: Psychemedics GAAP EPS of -$0.29, revenue of $6.44M
ACTON, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s largest provider of hair testing for drugs of abuse, announced today fourth quarter and full year financial results for the period ended December 31, 2021. The Company’s re...
News, Short Squeeze, Breakout and More Instantly...
Psychemedics Corporation Company Name:
PMD Stock Symbol:
NASDAQ Market:
Psychemedics Corporation Website:
DALLAS, June 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, proudly presents its inaugural Insights Report. This groundbreaking report offers a comprehensive analysis of drug trends in the workplace, drawing insights from a...
DALLAS, May 14, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, today announced financial results for the first quarter ended March 31, 2024. The Company’s revenue for the quarter ended March 31,...
DALLAS, March 28, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, announced today financial results for the year ended December 31, 2023. “2023 proved to be another challenging year due to the nega...